Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
RESEARCH TOOLSreports
HRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $3.93
Previous CloseN/A
Volume327.52K
Average Volume (3M)1.78M
Market Cap
$278.33M
Enterprise Value$411.49M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Feb 20, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding152,094,910
10 Day Avg. Volume1,266,010
30 Day Avg. Volume1,779,831
Standard Deviation0.27
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.02
Price to Cash Flow (P/CF)20.60
P/FCF Ratio23.70
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.64
Enterprise Value/Ebitda-18.53
Forecast
1Y Price Target
$6.50Price Target Upside284.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Heron Therapeutics News
PremiumCompany Announcements
Heron Therapeutics Relocates Headquarters to North Carolina
PremiumMarket News
3 Penny Stocks to Watch Now, 12/5/24
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst maintains a Buy rating based on the expected 4Q bounce-back with sales of $37MM-$43MM and positive adjusted EBITDA, along with the near-term removal of an overhang with the imminent decision in the Cinvanti patent lawsuit.
Legal VictoryThe U.S. District Court for the District of Delaware found that Cinvanti patents were valid and infringed upon by Fresenius, eliminating the threat of a potential near-term generic Cinvanti launch.
Product GrowthThe focus for 2025 will be on Zynrelef growth, which should benefit from the fully-deployed CrossLink promotion, the new VAN product, and streamlined reimbursement via NOPAIN.
Bears Say
Earnings MissHRTX reported 3Q24 top-line of $32.8MM, a significant miss vs. the Street's $36.8MM.
Financial PerformanceHRTX reported 3Q24 top-line of $32.8MM, a significant miss vs. the Street's $36.8MM.
Product PerformanceThe main disappointment was the CINV franchise, especially Cinvanti, which ticked down due to what appears to be quarterly fluctuations.
---
Ownership Overview
5.20% Insiders
8.78% Mutual Funds
1.68% Other Institutional Investors
75.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRTX FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $1.04 and its highest was $3.93 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $278.33M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 15 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.008.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 152,094,910 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went down -30.435%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Among the largest hedge funds holding Heron Therapeutics’s share is EntryPoint Capital, LLC. It holds Heron Therapeutics’s shares valued at 30K.
---
Heron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (284.62% Upside)
$6.50 (284.62% Upside)
Blogger Sentiment
Bearish
HRTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 221.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.01%
12-Months-Change
Fundamentals
Return on Equity
69.91%
Trailing 12-Months
Asset Growth
-3.67%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
---
HRTX Company Deck
---
HRTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with significant achievements, including revenue growth, cost management, and strategic advancements like the VAN approval and NOPAIN Act inclusion. However, challenges remain with specific product revenue declines and financial write-offs.Read More>---
HRTX Stock 12 Month Forecast
Average Price Target
$6.50
▲(284.62% Upside)
Technical Analysis
Best Analysts Covering HRTX
1 Year
1 Year Success Rate
5/28 ratings generated profit
1 Year Average Return
-25.80%
initiated a buy rating 2 months ago
Copying Carl Byrnes's trades and holding each position for 1 Year would result in 17.86% of your transactions generating a profit, with an average return of -25.80% per trade.
---